Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions
Clinical translation of tolerance-inducing cell therapies requires a novel approach focused on innovative networks, patient involvement and, foremost, a fundamental paradigm shift in thinking from both Academia, Industry and Regulatory Agencies. Tolerance-inducing cell products differ essentially f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00392/full |
| _version_ | 1818992134861094912 |
|---|---|
| author | Anja eTen Brinke Irma eJoosten S. Marieke evan Ham Cees evan Kooten Berent Jan Prakken |
| author_facet | Anja eTen Brinke Irma eJoosten S. Marieke evan Ham Cees evan Kooten Berent Jan Prakken |
| author_sort | Anja eTen Brinke |
| collection | DOAJ |
| description | Clinical translation of tolerance-inducing cell therapies requires a novel approach focused on innovative networks, patient involvement and, foremost, a fundamental paradigm shift in thinking from both Academia, Industry and Regulatory Agencies. Tolerance-inducing cell products differ essentially from conventional drugs. They are personalized and target interactive immunological networks to shift the balance towards tolerance. The human cell products are often absent or fundamentally different in animals. This creates important limitations of pre-clinical animal testing for safety and efficacy of these products and calls for novel translational approaches, which require the combined efforts of the different parties involved. Dedicated international and multidisciplinary consortia that focus on clinical translation are of utmost importance. They can help inform and educate regulatory policy makers on the unique requirements for these cell products, ranging from preclinical studies in animals to in vitro human studies. In addition, they can promote reliable immunomonitoring tools. The development of tolerance-inducing cell products requires not only bench-to-bedside but also reverse translation, from bedside back to the bench. |
| first_indexed | 2024-12-20T20:21:20Z |
| format | Article |
| id | doaj.art-911d57a66f284925aaf33fa9a773b620 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T20:21:20Z |
| publishDate | 2014-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-911d57a66f284925aaf33fa9a773b6202022-12-21T19:27:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242014-08-01510.3389/fimmu.2014.00392102464Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactionsAnja eTen Brinke0Irma eJoosten1S. Marieke evan Ham2Cees evan Kooten3Berent Jan Prakken4Sanquin Blood Supply FoundationRadboud University Medical Center, NijmegenSanquin Blood Supply FoundationLeiden University Medical CenterUniversity Medical Centre Utrecht, Wilhelmina Children's HospitalClinical translation of tolerance-inducing cell therapies requires a novel approach focused on innovative networks, patient involvement and, foremost, a fundamental paradigm shift in thinking from both Academia, Industry and Regulatory Agencies. Tolerance-inducing cell products differ essentially from conventional drugs. They are personalized and target interactive immunological networks to shift the balance towards tolerance. The human cell products are often absent or fundamentally different in animals. This creates important limitations of pre-clinical animal testing for safety and efficacy of these products and calls for novel translational approaches, which require the combined efforts of the different parties involved. Dedicated international and multidisciplinary consortia that focus on clinical translation are of utmost importance. They can help inform and educate regulatory policy makers on the unique requirements for these cell products, ranging from preclinical studies in animals to in vitro human studies. In addition, they can promote reliable immunomonitoring tools. The development of tolerance-inducing cell products requires not only bench-to-bedside but also reverse translation, from bedside back to the bench.http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00392/fullAutoimmunityDendritic CellsTransplantationtoleranceregulatory T cellsregulatory agencies |
| spellingShingle | Anja eTen Brinke Irma eJoosten S. Marieke evan Ham Cees evan Kooten Berent Jan Prakken Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions Frontiers in Immunology Autoimmunity Dendritic Cells Transplantation tolerance regulatory T cells regulatory agencies |
| title | Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| title_full | Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| title_fullStr | Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| title_full_unstemmed | Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| title_short | Redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| title_sort | redefining strategies to introduce tolerance inducing cellular therapy in humans to combat autoimmunity and transplantation reactions |
| topic | Autoimmunity Dendritic Cells Transplantation tolerance regulatory T cells regulatory agencies |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00392/full |
| work_keys_str_mv | AT anjaetenbrinke redefiningstrategiestointroducetoleranceinducingcellulartherapyinhumanstocombatautoimmunityandtransplantationreactions AT irmaejoosten redefiningstrategiestointroducetoleranceinducingcellulartherapyinhumanstocombatautoimmunityandtransplantationreactions AT smariekeevanham redefiningstrategiestointroducetoleranceinducingcellulartherapyinhumanstocombatautoimmunityandtransplantationreactions AT ceesevankooten redefiningstrategiestointroducetoleranceinducingcellulartherapyinhumanstocombatautoimmunityandtransplantationreactions AT berentjanprakken redefiningstrategiestointroducetoleranceinducingcellulartherapyinhumanstocombatautoimmunityandtransplantationreactions |